Ever Supreme Bio Technology Co.,Ltd.
Year established: 2016
 | Registered capital TWD 752M
 | Employees 90

Ever Supreme, a pioneering leader in the fields of immune cell therapy and stem cell drug development, is proud to introduce the revolutionary "off-the-shelf" CAR001 therapy for solid tumors, encompassing colorectal cancer, breast cancer, GBM, and lung cancer. This innovative therapy harnesses the power of BiTE-secreting CAR-γδT cells and has recently garnered approval for a Phase I/IIa trial by the US FDA this year.

Our UMSC01 therapy, featuring allogeneic umbilical cord mesenchymal stem cells, is US FDA and TFDA approved, addressing critical conditions such as acute myocardial infarction, acute ischemic stroke, multiple sclerosis, and COVID-19.

In addition to our proprietary therapies, Ever Supreme offers cell products like ADCV, DC-CIK(WT1), CIK, and GDT, adhering to Taiwan FDA's 2018 Regulations Governing Specific Cellular Therapeutic Technology. These products support the advancement of cellular therapeutic technology.

Ever Supreme is actively seeking out-licensing, joint venture, and related business opportunities with partners who share their vision of improving patient health.
Regenerative Medicine